BioAtlaInc.
Pemetrexed (Alimta)(BioAtla, Inc.)은 Leptomeningeal Metastasis 표적 치료제로, NSCLC; Melanoma 영역에서 개발·상용화 중입니다. 작용기전: targeting epidermal growth factor and mesenchymal-epithelial transition receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 84% (ClinicalTrials.gov NCT04194944). PK: t½ 3.5 h. 차별점: uniquely enables the simultaneous investigation of tumor-specific vulnerabilities, stromal contributions to drug resistance, a.
Leptomeningeal Metastasis
NSCLC; Melanoma
Recruiting
bispecific antibody targeting epidermal growth factor and mesenchymal-
uniquely enables the simultaneous investigation of tumor-specific vulnerabilities, stromal contributions to drug resistance, a
targeting epidermal growth factor and mesenchymal-epithelial transition receptor
Cytokine Release Syndrome Induced by Immune Checkpoint Inhibitor Therapy: A Case Report
apoptosis, DNA repair, and immune evasion
PD-L1 expression
resistance mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
BioAtlaInc.
Pemetrexed (Alimta)(BioAtla, Inc.)은 Leptomeningeal Metastasis 표적 치료제로, NSCLC; Melanoma 영역에서 개발·상용화 중입니다. 작용기전: targeting epidermal growth factor and mesenchymal-epithelial transition receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 84% (ClinicalTrials.gov NCT04194944). PK: t½ 3.5 h. 차별점: uniquely enables the simultaneous investigation of tumor-specific vulnerabilities, stromal contributions to drug resistance, a.
Leptomeningeal Metastasis
NSCLC; Melanoma
Recruiting
bispecific antibody targeting epidermal growth factor and mesenchymal-
uniquely enables the simultaneous investigation of tumor-specific vulnerabilities, stromal contributions to drug resistance, a
targeting epidermal growth factor and mesenchymal-epithelial transition receptor
Cytokine Release Syndrome Induced by Immune Checkpoint Inhibitor Therapy: A Case Report
apoptosis, DNA repair, and immune evasion
PD-L1 expression
resistance mechanisms
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.